New Insights into Post-Menopausal Osteoporosis Treatment

Recent research from AIIMS in New Delhi sheds light on the complexities of post-menopausal osteoporosis, revealing that factors beyond calcium deficiency contribute to the condition. The study highlights the role of gut health and immune system balance in bone density loss. Utilizing the probiotic Bacillus coagulans, researchers observed promising results in mice, paving the way for future clinical trials in humans. Experts believe that targeting gut health could significantly change treatment approaches for osteoporosis in women. Read on to learn more about these exciting developments.

By Narendra Chaudhary Jan 21, 2026, 18:45 IST

Breakthrough Research on Osteoporosis

Millions of women experience pain and frequent fractures due to weakened bones after menopause. Recent findings from the All India Institute of Medical Sciences (AIIMS) in New Delhi offer promising avenues for treatment. The study indicates that deficiencies in calcium or vitamin D are not the only culprits; rather, an imbalance involving the gut, immune system, and bone health significantly contributes to this condition.

Identifying the Underlying Causes

Identifying the Underlying Causes
Hormonal shifts post-menopause disrupt the beneficial gut bacteria and the immune response, leading to heightened activity of bone-resorbing cells known as osteoclasts, which accelerates bone density loss.

Promising Research Findings

Promising Research Findings
The AIIMS study created a model for post-menopausal osteoporosis and tested it on mice. They utilized a safe probiotic, 'Bacillus coagulans', which resulted in reduced gut inflammation and marked improvements in bone density. Following these encouraging results, preparations for human clinical trials are now in progress.

Potential for Reducing Bone Loss

Potential for Reducing Bone Loss
Bacillus coagulans enhances the production of short-chain fatty acids, particularly butyrate, in the gut. This compound plays a crucial role in managing inflammation and decelerating bone loss, forming the foundation for a new therapeutic approach.

Expert Insights

Expert Insights
Dr. JB Sharma, a former professor at AIIMS, emphasizes that osteoporosis is often a silent condition in post-menopausal women, with fractures occurring too late for effective intervention. A drug targeting the gut and immune system could revolutionize treatment strategies.

Dr. Rupesh Srivastava from the Department of Biotechnology at AIIMS highlights that the research clearly indicates that post-menopausal osteoporosis is not merely a result of calcium deficiency but stems from an imbalance among the gut, immune system, and bones. The positive outcomes observed in mice provide a solid groundwork for future drug development.

Stay Updated

PC Social Media